Medication info

Boryung Pregabalin Capsule 50 mg

Prescription medicationOralExpired
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Boryung Co., Ltd.
Appearance
Hard capsule with a dark blue upper part and a white lower part containing white or pale yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 202001269 · Approved 2020.02.21

This product's status changed to Expired on 2025.02.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be done gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis. (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and Adolescent Patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12–17 years because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also effective as an adjunctive therapy for partial seizures in patients with epilepsy, whether or not they are accompanied by secondary generalization. It is utilized in the treatment of fibromyalgia, helping to alleviate pain. It is used for various neurological and pain-related disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is excreted mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be done gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis. (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and Adolescent Patients Administration is not recommended in children under 12 years of age or adolescent patients aged 12–17 years because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if there are changes in mood or behavior during treatment, consult a doctor immediately. Do not take if there is an allergy to any ingredients in this medication or have certain genetic conditions like lactose intolerance. Patients with diabetes may experience weight gain while taking this medication, which may require dosage adjustments for blood sugar control. If symptoms of angioedema occur, stop taking the medication immediately and notify healthcare professionals. Elderly patients may experience dizziness or drowsiness while taking this medication, so caution is required. Activities with risk should be avoided if such symptoms occur. This medication can cause visual disturbances such as blurred vision or changes in eyesight; if symptoms persist, consult a physician. Abrupt discontinuation of this medication can lead to withdrawal symptoms, such as insomnia, headache, nausea, anxiety, so dosage should be reduced gradually under a doctor's guidance. There is a risk of drug abuse, so patients with a history of drug abuse should be particularly cautious and report any unusual behavior to their healthcare provider immediately. Patients with impaired kidney function may require dosage adjustments. Those with heart disease or congestive heart failure should consult a doctor before taking this medication. Caution is required when taking this medication with opioid analgesics due to the risk of central nervous system depression. Patients with respiratory or neurological diseases or who are elderly may have a higher risk of respiratory depression and may require dosage adjustments. During early pregnancy, taking this medication may pose risks to the fetus, so women who are pregnant or planning to become pregnant should consult a doctor and use effective contraception. Breastfeeding women should discuss with a doctor the potential transmission of this medication through breast milk and consider stopping breastfeeding or medication. Dizziness or drowsiness can occur while taking this medication, so it is advisable to avoid dangerous activities like driving or operating machinery. Severe skin reactions may rarely occur, and if there are any abnormal skin symptoms, discontinue use immediately and inform healthcare professionals. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, which require urgent medical attention, so immediate hospital visit is necessary. This medication must be kept out of reach of children, and caution is required when transferring it to other containers, as it may cause accidents.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, depression, euphoria, decreased libido, depersonalization, paraphilia, restlessness, anxiety, mood disturbances, emotional downturn, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to suppress, apathy, ataxia, abnormal motor coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonic jerks, reduced reflexes, abnormal movements, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, hypokinesia, olfactory disturbances, taste loss, writing difficulties, diplopia, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, joint pain, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feelings of intoxication, sensory disturbances, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, elevated alanine aminotransferase, increased serum creatine phosphokinase, elevated aspartate aminotransferase, increased blood sugar, decreased platelet count, reduced serum potassium, weight loss, elevated serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, convulsions, affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect from air and moisture. It is important to maintain storage temperature at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Hard capsule with a dark blue upper part and a white lower part containing white or pale yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.